hepat
occur
sporad
epidem
worldwid
tendenc
cyclic
recurr
lemon
epidem
uncommon
develop
countri
adult
gener
immun
poor
sanit
hygien
condit
differ
part
world
leav
larg
segment
popul
suscept
infect
outbreak
may
result
whenev
viru
introduc
lemon
melnick
shapiro
margoli
worldwid
hav
infect
account
million
case
annual
viral
hepat
prevent
board
hepat
b
viru
hbv
infect
seriou
global
health
problem
billion
peopl
infect
worldwid
million
suffer
chronic
hbv
infect
tenth
lead
caus
death
worldwid
hbv
infect
result
million
death
per
year
caus
chronic
hepat
cirrhosi
hepatocellular
carcinoma
last
account
death
per
year
fact
sheet
hepat
b
viru
hbv
infect
major
global
public
health
problem
approxim
billion
peopl
infect
worldwid
million
act
chronic
carrier
hbv
fact
sheet
approxim
infect
patient
develop
cirrhosi
liver
failur
hepatocellular
carcinoma
lok
hbv
infect
account
million
death
year
mahoney
lee
tenth
lead
caus
death
worldwid
sinc
discoveri
hepat
c
viru
hcv
recogn
major
caus
chronic
liver
diseas
worldwid
recent
estim
preval
hcv
infect
repres
million
peopl
perz
et
al
hcv
lead
caus
liver
transplant
develop
countri
common
chronic
bloodborn
infect
usa
wide
rang
preval
estim
among
develop
countri
gener
less
data
avail
valid
assumpt
burden
diseas
develop
world
rang
preval
reflect
review
estim
develop
countri
among
world
popul
nation
popul
refer
bureau
china
whose
citizen
account
onefifth
world
popul
report
seropreval
xia
et
al
india
hold
addit
onefifth
world
popul
one
communitybas
survey
report
overal
rate
chowdhuri
et
al
countri
highest
report
preval
rate
locat
africa
asia
area
lower
preval
includ
industri
nation
north
america
northern
western
europ
australia
popul
nation
develop
world
rel
low
rate
hcv
seropreval
includ
germani
palitzsch
et
al
canada
zou
et
al
franc
desenclo
australia
law
et
al
australian
censu
low
slightli
higher
seropreval
rate
report
usa
alter
et
al
japan
ohshima
et
al
itali
human
papillomaviru
hpv
caus
cervic
cancer
second
biggest
caus
femal
cancer
mortal
worldwid
estim
number
cervic
cancer
death
around
per
year
preval
genit
hpv
infect
world
around
million
genotyp
hpv
infect
human
mucos
area
upper
digest
tract
genit
tract
major
adenocarcinoma
cervix
squamou
cell
cancer
scc
vulva
vagina
peni
anu
caus
togeth
account
case
global
remain
due
highrisk
hpv
type
rel
import
differ
highrisk
type
vari
countri
region
type
greatest
contribut
cervic
cancer
region
hpv
also
associ
cancer
anu
head
neck
rare
recurr
respiratori
papillomatosi
children
case
cervic
cancer
estim
occur
year
occur
develop
countri
neither
populationbas
routin
screen
eg
papanicola
smear
test
optim
treatment
avail
highest
estim
incid
rate
cervic
cancer
occur
africa
central
south
america
asia
epidemiolog
studi
usa
report
popul
infect
genit
hpv
lifetim
transient
infect
persist
infect
confirm
detect
hpv
dna
genit
sampl
mild
cytolog
sign
clinic
lesion
hpv
belong
famili
papovavirida
small
nonenvelop
icosahedr
virus
kbp
long
doublestrand
circular
dna
genom
papillomaviru
genom
compris
earli
late
gene
encod
earli
protein
late
protein
earli
protein
nonstructur
protein
involv
replic
transcript
genom
host
cell
tumor
transform
wherea
structur
capsid
protein
virion
lowgrad
cervic
dysplasia
correspond
product
infect
cell
activ
shed
viru
wherea
highgrad
dysplasia
cancer
produc
virion
viral
gene
express
cell
limit
oncogen
transcrib
randomli
integr
viral
dna
protein
thought
induc
cell
prolifer
disrupt
cell
cycl
regul
inactiv
rb
famili
protein
wherea
block
cell
apoptosi
direct
tumor
suppressor
protein
proteasom
prophylact
hpv
vaccin
candid
base
recombin
capsid
protein
aim
elicit
neutral
antivir
antibodi
protect
infect
therapeut
vaccin
candid
base
viral
oncogen
protein
without
aim
induc
cellmedi
immun
respons
elimin
transform
tumor
cell
advanc
promis
approach
prophylact
vaccin
involv
use
noninfecti
recombin
viruslik
particl
vlp
selfassembl
spontan
pentam
capsid
protein
two
prophylact
vaccin
candid
level
phase
iii
clinic
evalu
compani
file
licensur
gsk
focus
bival
vlp
vaccin
candid
merck
develop
tetraval
vaccin
base
vlp
show
high
efficaci
proofofprincipl
studi
manufactur
announc
result
show
almost
protect
highgrad
cervic
cancer
precursor
caus
hpv
type
women
age
year
hpv
infect
young
femal
temporari
littl
longterm
signific
seventi
percent
infect
gone
year
year
howev
infect
persist
infect
women
high
risk
develop
precancer
lesion
cervix
progress
invas
cervic
cancer
process
usual
take
year
provid
mani
opportun
detect
treatment
precancer
lesion
progress
invas
cancer
almost
alway
prevent
standard
prevent
strategi
appli
lesion
still
caus
consider
burden
necessit
prevent
surgeri
mani
case
involv
loss
fertil
develop
countri
cervic
screen
use
papanicola
pap
test
liquidbas
cytolog
use
detect
abnorm
cell
may
develop
cancer
abnorm
cell
found
women
invit
colposcopi
colposcop
inspect
biopsi
taken
abnorm
area
remov
simpl
procedur
typic
cauter
loop
commonli
develop
world
freez
cryotherapi
treat
abnorm
cell
way
prevent
develop
cervic
cancer
pap
smear
reduc
incid
fatal
cervic
cancer
develop
world
even
case
death
usa
cervic
cancer
substanti
mortal
resourcepoor
area
worldwid
estim
case
death
year
kahn
sever
influenza
epidem
twentieth
centuri
caus
million
death
worldwid
includ
worst
epidem
american
histori
spanish
influenza
outbreak
kill
season
influenza
acut
viral
infect
caus
influenza
viru
three
type
season
influenza
b
c
type
influenza
virus
type
subtyp
accord
differ
kind
combin
viru
surfac
protein
among
mani
subtyp
influenza
virus
current
influenza
subtyp
circul
among
human
influenza
virus
circul
everi
part
world
type
c
influenza
case
occur
much
less
frequent
b
influenza
b
virus
includ
season
influenza
vaccin
avian
influenza
human
avian
influenza
infecti
diseas
bird
spread
peopl
difficult
transmit
person
person
almost
peopl
infect
close
contact
infect
bird
environ
peopl
becom
infect
mortal
rate
get
swine
influenza
virus
siv
caus
diseas
human
howev
countri
report
case
human
infect
siv
human
infect
mild
virus
spread
peopl
viru
caus
influenza
pandem
thought
origin
swine
exampl
siv
abl
spread
easili
among
peopl
also
caus
diseas
hiv
human
immunodefici
viru
viru
lead
acquir
immun
defici
syndrom
aid
cdc
estim
peopl
unit
state
contract
hiv
two
type
hiv
usa
unless
otherwis
note
term
hiv
primarili
refer
type
hiv
damag
person
bodi
destroy
specif
blood
cell
call
cell
crucial
help
bodi
immun
defens
aid
late
stage
hiv
infect
person
immun
system
get
sever
damag
feel
difficulti
fight
diseas
certain
cancer
develop
certain
medic
peopl
hiv
could
progress
aid
year
time
cure
hiv
infect
despit
major
advanc
diagnos
treat
hiv
infect
case
aid
diagnos
death
among
peopl
live
hiv
report
usa
abovediscuss
diseas
continu
threaten
whole
world
insist
search
explor
new
medicin
concept
manag
would
possibl
peopl
may
live
long
diseasefre
free
econom
burden
understand
incred
complex
biolog
hiv
viru
essenti
build
effect
diagnost
drug
hiv
belong
class
virus
known
retrovirus
contain
ribonucl
acid
rna
genet
materi
hiv
viru
infect
cell
use
enzym
call
revers
transcriptas
convert
rna
dna
replic
use
host
cell
replic
machineri
hiv
replic
cycl
begin
fusion
viru
host
cell
surfac
begin
influx
viral
protein
host
cell
viral
dna
form
revers
transcript
integr
host
dna
new
viral
rna
use
genom
rna
make
viral
protein
travel
cell
surfac
form
new
hiv
viru
viciou
cycl
rapidli
produc
sever
billion
new
virus
everi
day
person
infect
hiv
complic
abil
revers
transcriptas
mutat
caus
new
strain
hiv
develop
infect
individu
hiv
target
immun
system
directli
infect
lymphocyt
also
lead
systemat
degrad
immun
system
cell
pivot
help
immun
respons
blum
constant
process
evolut
replic
hiv
viru
creat
incred
stress
immun
system
one
reason
hiv
especi
difficult
medic
research
combat
drug
hiv
call
antiretrovir
drug
hiv
consid
retroviru
previous
describ
drug
fall
three
class
consist
underli
biolog
viru
nucleosid
revers
transcriptas
inhibitor
nrti
nonnucleosid
revers
transcriptas
inhibitor
nnrti
proteas
inhibitor
pi
pirmoham
revers
transcriptas
inhibitor
directli
inhibit
reproduct
capac
hiv
viru
mandatori
role
revers
transcriptas
enzym
play
viral
reproduct
nrti
contain
faulti
version
nucleotid
use
revers
transcriptas
convert
rna
dna
caus
improp
build
new
dna
hiv
genet
materi
incorpor
healthi
genet
materi
host
cell
hand
nnrti
work
attach
revers
transcriptas
prevent
enzym
convert
rna
dna
viral
rna
translat
polypeptid
sequenc
sequenc
assembl
long
chain
includ
protein
like
revers
transcriptas
proteas
purpos
resist
test
make
avail
inform
assist
select
antiretrovir
regimen
like
achiev
maintain
viral
suppress
guidelin
come
result
hiv
drug
resist
test
perform
hivinfect
person
enter
clinic
care
whether
treat
immedi
aim
strategi
detect
chanc
transmit
resist
maximum
possibl
hivinfect
individu
receiv
antiretrovir
therapi
resist
test
perform
presenc
virolog
failur
ensur
adequ
perform
resist
test
rna
level
least
copiesml
time
test
although
guidelin
agre
resist
test
could
also
attempt
individu
rna
level
copiesml
howev
last
group
patient
chanc
amplifi
sequenc
markedli
lower
drug
resist
test
might
also
help
manag
suboptim
viral
load
reduct
howev
less
clear
addit
switch
new
antiretrovir
drug
could
help
achiev
viral
suppress
importantli
given
drug
resist
mutat
wane
treatment
interrupt
drug
resist
test
set
virolog
failur
perform
patient
take
hisher
antiretrovir
drug
within
week
discontinu
therapi
two
type
antiretrovir
resist
assay
current
avail
assist
clinician
assess
hiv
resist
genotyp
assay
phenotyp
assay
hanna
aquila
hirsch
et
al
two
test
also
mark
use
sampl
rna
level
copiesml
tabl
show
common
assay
along
advantag
disadvantag
test
limit
sensit
detect
minor
variant
viral
popul
detect
nonb
subtyp
may
limit
test
last
least
result
requir
expert
interpret
addit
genotyp
test
use
gener
predict
phenotyp
refer
virtual
phenotyp
virtual
phenotyp
viral
sequenc
genotyp
enter
databas
consist
pair
genotyp
phenotyp
order
deriv
estim
phenotyp
recent
investig
employ
newer
techniqu
allelespecif
pcr
singlegenom
ultradeep
sequenc
assess
role
minor
hiv
variant
harbor
drug
resist
detect
current
standard
genotyp
phenotyp
assay
hirsch
et
al
tabl
show
recent
advanc
resist
test
minor
level
thu
current
emerg
techniqu
like
sequenc
microarray
realtim
pcr
revolution
modern
concept
medicin
ie
wellknown
person
medicin
concept
treatment
base
individu
genom
composit
well
genet
makeup
infect
agent
strain
one
import
aspect
person
medicin
patienttopati
variat
drug
respons
pharmacogenom
address
issu
seek
identifi
genet
contributor
human
variat
drug
efficaci
toxic
viral
diseas
go
discuss
current
updat
success
challeng
field
evolv
studi
singl
candid
gene
comprehens
genomewid
analys
thu
new
field
ultim
open
new
vista
understand
better
manag
fatal
viral
diseas
effect
person
clinic
treatment
strategi
may
develop
recent
emerg
progress
molecular
biolog
techniqu
make
rout
easier
select
right
target
variou
tradit
modern
genom
approach
nowaday
practic
thu
one
major
challeng
identifi
character
target
essenti
viru
surviv
absent
significantli
diverg
mammalian
host
may
sort
drug
discoveri
viral
diseas
small
genom
rel
viral
protein
make
process
fairli
straightforward
modern
molecular
techniqu
like
realtim
pcr
microarray
nextgen
sequenc
approach
current
give
precis
specif
result
thu
help
progress
newer
therapeut
approach
tabl
show
variou
molecular
techniqu
target
select
quantit
analysi
base
viral
load
assay
viral
load
assay
express
copi
number
given
unit
plasma
usual
use
copiesml
altern
express
intern
unit
suggest
iuml
base
interlaboratori
standard
use
three
fdaapprov
viral
load
kit
exchang
relationship
copiesml
iuml
viral
load
dynam
rel
paramet
valu
chang
depend
method
use
fluctuat
even
daili
basi
varianc
repeat
test
use
kit
usual
smaller
determin
differ
method
thu
dynam
comparison
viral
load
valu
use
assay
method
time
strongli
suggest
hiv
viral
load
multipl
clinic
implic
report
global
aid
epidem
torti
et
al
firstli
current
serv
complementari
diagnosi
hiv
infect
may
becom
one
diagnosi
standard
near
futur
qualit
determin
hiv
infect
higher
viral
load
valu
measur
confid
diagnosi
hiv
infect
drawn
exampl
viral
load
higher
copiesml
probabl
hiv
infect
individu
sampl
taken
significantli
high
particularli
high
viral
load
repeat
anoth
sampl
taken
individu
differ
time
secondli
viral
load
help
earli
diagnosi
hiv
infect
report
viral
burst
blood
earli
stage
hiv
infect
viral
load
earli
stage
sometim
even
higher
diseas
stage
aid
viral
load
assay
also
use
complementari
diagnosi
hiv
infect
neonat
hivinfect
mother
although
antibodybas
hiv
assay
diagnosi
standard
clinic
practic
useless
window
period
earli
stage
infect
diagnost
valu
infant
hivinfect
mother
discuss
earlier
thirdli
analysi
viral
load
effici
paramet
assess
antivir
therapi
effect
standard
viral
load
decreas
least
log
log
antivir
therapi
viral
load
reduc
copiesml
therapi
final
viral
load
valu
predict
progress
aid
exampl
viral
load
predict
probabl
p
valu
becom
aid
year
patient
normal
count
p
valu
viral
load
less
copiesml
p
valu
dramat
increas
viral
load
copiesml
count
less
viral
load
use
predict
shorter
progress
aid
probabl
turn
aid
within
month
viral
carrier
proport
associ
viral
load
valu
similar
conclus
drawn
recent
clinic
trial
includ
hivinfect
patient
haart
torti
et
al
patient
higher
tcell
count
follow
treatment
appear
surviv
month
wherea
increas
hiv
rna
copiesml
three
method
current
employ
commerci
kit
viral
load
assay
rtpcr
b
dna
nasbabas
assay
tabl
show
comparison
three
fdaapprov
viral
load
assay
commonli
use
assess
advantag
disadvantag
major
differ
assay
requir
specif
equip
rather
sensit
specif
therefor
resourc
variou
set
remain
determin
factor
choos
pcrbase
hybridizationbas
isotherm
amplificationbas
hiv
detect
assay
polymeras
chain
reaction
pcr
rtpcrbase
assay
frequent
use
technolog
molecular
biolog
molecular
diagnost
pcrbase
assay
use
either
qualit
quantit
analysi
hiv
hiv
retroviru
pcr
rtpcr
use
qualit
assay
viral
infect
target
integr
form
proviru
free
hiv
respect
rtpcr
howev
specif
requir
hiv
viral
load
assay
amplifi
product
pcr
rtpcr
visual
varieti
method
agaros
gel
electrophoresi
realtim
visual
enzymat
reaction
one
commerci
kit
amplicor
use
enzymat
reaction
product
visual
micropl
platform
murphi
et
al
consid
complic
procedur
amplicor
assay
postamplif
hybrid
enzymat
reaction
visual
involv
multipl
step
mani
type
reagent
realtim
visual
advantag
develop
new
rtpcrbase
assay
hiv
viral
load
analysi
steven
et
al
simplic
shorter
time
requir
finish
test
make
rtpcrbase
hiv
viral
load
assay
competit
among
avail
kit
possibl
one
focu
futur
kit
develop
amplifi
product
nucleic
acidbas
method
electrophoret
analyz
fluoresc
visual
realtim
pattern
singlemolecul
identif
nonspecif
fluoresc
dye
sybr
green
chosen
current
clinic
pharmacolog
laboratori
use
approach
highfidel
dna
polymeras
differ
taq
polymeras
exonucleas
activ
former
exonucleas
activ
proofread
function
latter
exonucleas
activ
differ
differenti
employ
realtim
visual
pcramplifi
product
taq
polymeras
use
taqman
technolog
wherea
realtim
visual
assay
use
mutationsensit
onoff
switch
mediat
highfidel
dna
polymeras
depend
molecular
beacon
fret
molecular
beacon
structur
targetindepend
sequenc
design
end
primer
molecular
beacon
mix
targetspecif
sequenc
loop
targetindepend
sequenc
hairpin
mix
beacon
add
one
short
fragment
identifi
thu
help
enhanc
specif
assay
similarli
combin
mutationsensit
onoff
switch
fret
technolog
also
add
addit
sequenc
fragment
discrimin
test
mutationsensit
onoff
switch
offer
high
sensit
specif
nucleic
acid
identificationmut
detect
combin
fluoresc
realtim
visual
make
highli
competit
technolog
develop
qualit
quantit
assay
hiv
infect
snp
detect
use
predict
advers
event
antiretrovir
therapi
patient
hiv
infect
abo
et
al
potenti
clinic
valu
pharmacogenet
approach
predict
drug
toxic
uncov
candid
polymorph
discov
applic
genotyp
strategi
predict
antiretrovir
drug
efficaci
recent
emerg
varieti
clinic
set
genotyp
resist
test
hiv
isol
demonstr
clinic
use
provid
way
assist
therapeut
decis
make
patient
whose
hiv
rna
level
rise
klein
et
al
moreov
hiv
viral
load
test
serv
major
guid
select
mainten
antiretrovir
therapi
sagreiya
et
al
develop
print
spot
genom
microarray
enabl
rapid
accumul
new
inform
concern
gene
mutat
express
human
microarray
use
gene
mutat
snp
well
provid
rapid
screen
inform
regard
mrna
express
transcript
profil
abil
gener
hundr
thousand
data
point
requir
sophist
complex
inform
system
necessari
accur
use
data
analysi
techniqu
gener
wealth
new
inform
drug
biomark
target
discoveri
pharmacogenom
drug
efficaci
test
well
known
carcinogen
human
papillomavirus
hpv
causal
agent
cervic
cancer
hpv
infect
extrem
common
rel
rare
cancer
incid
indic
mani
infect
spontan
resolv
schiffman
et
al
persist
without
progress
host
genet
factor
may
play
role
cervic
carcinogenesi
thought
influenc
develop
persist
hpv
infect
perhap
progress
cancer
czene
et
al
hemminki
chen
hemminki
et
al
hussain
et
al
hildesheim
wang
carrington
et
al
role
host
genet
factor
cofactor
associ
cervic
cancer
summar
tabl
discuss
safaeian
et
al
particularli
interest
stepwis
pathogenesi
diseas
extens
studi
initi
hpv
infect
cervic
transform
zone
subsequ
step
relat
viral
persist
progress
precanc
invas
schiffman
et
al
differ
factor
associ
step
toward
pathogenesi
role
nongenet
cofactor
persist
progress
well
studi
fewer
studi
host
genet
role
pathogenesi
cervic
cancer
current
therapi
chronic
viral
hepat
includ
two
regimen
ifn
antivir
nucleosidenucleotid
analogu
lamivudin
adefovir
dipivoxil
ribavirin
marcellin
et
al
chander
et
al
ifn
lamivudin
alon
control
hepat
b
onethird
patient
marcellin
et
al
liaw
combin
ifn
ribavirin
standard
therapi
hepat
c
result
erad
hcv
patient
chander
et
al
mchutchison
et
al
outcom
viral
therapi
influenc
viral
load
viral
genom
variat
especi
viral
genotyp
certain
specif
genom
variant
variou
therapeut
agent
show
variat
efficaci
treatment
tabl
show
suscept
variou
genotyp
viral
diseas
hepat
tabl
show
therapeut
agent
effect
drug
efficaci
variou
genotypestrain
hepat
addit
major
histocompat
complex
mhc
class
mhc
class
ii
polymorph
thursz
thoma
interleukin
polymorph
yee
et
al
mxa
promot
singlenucleotid
polymorph
snp
mannosebind
protein
snp
hijikata
et
al
support
affect
host
immun
antivir
respons
thu
associ
diseas
progress
treatment
respons
human
bodi
humor
ifn
serv
first
line
cellular
defens
control
viral
infect
ifninduc
molecul
lead
effect
control
viral
expans
either
inhibit
viral
replic
promot
infect
cell
undergo
apoptosi
supposedli
combin
molecul
person
determin
individu
vari
degre
respons
ifn
treatment
howev
gene
encod
molecul
conserv
human
certain
genet
polymorph
recent
gwa
articl
link
genotyp
ifnalpha
therapeut
respons
trigger
intens
research
establish
underli
mechan
associ
liapaki
jacobson
point
possibl
explan
strong
mechanist
clue
thio
thoma
specul
variant
correl
regul
cytokin
transcript
snp
locat
upstream
gene
thio
thoma
observ
cite
earlier
suppiah
colleagu
tanaka
colleagu
strongli
suggest
identifi
snp
inde
alter
express
perhap
gene
suppiah
et
al
tanaka
et
al
two
studi
found
carri
g
risk
allel
snp
lower
mrna
express
cytokin
peripher
blood
mononuclear
cell
suppiah
et
al
tanaka
et
al
hand
ge
colleagu
report
differ
cytokin
express
peripher
blood
mononuclear
cell
hcvuninfect
person
homozyg
proxi
allel
snp
use
snpexpress
databas
ge
et
al
thu
variou
snp
show
variat
respons
tabl
show
signific
predictor
drug
respons
present
earlier
least
four
independ
gwa
studi
provid
signific
evid
role
gene
pathogenesi
hcv
infect
ge
et
al
suppiah
et
al
howev
still
piec
data
need
complet
mechanist
pictur
thio
thoma
gene
encod
one
recent
discov
type
iii
interferon
lambda
interferon
belong
superfamili
dellgren
et
al
type
iii
interferon
cytokin
murin
studi
reveal
preferenti
express
ifnlambda
receptor
epitheli
surfac
suggest
type
iii
interferon
may
allow
host
rapidli
elimin
virus
major
portal
entri
bodi
infect
establish
without
activ
arm
immun
system
ank
et
al
ank
paludan
nonetheless
one
import
differ
establish
murin
human
system
interleukin
liapaki
jacobson
receptor
alpha
chain
receptor
complex
induc
ifnlambda
express
human
hepatocyt
wherea
murin
liver
seem
unlik
respond
ifnlambda
ank
et
al
ank
paludan
find
suggest
ifnlambda
contribut
host
defens
hepatotrop
virus
hcv
human
like
type
interferon
lambda
interferon
activ
hcv
viral
infect
vitro
vivo
marcello
et
al
howev
vitro
exogen
ifnlambda
induc
slower
sustain
abund
ifnstimul
gene
ifnalpha
marcello
et
al
although
find
answer
ifnlambda
might
play
key
role
hcv
recoveri
explain
treatmentassoci
resolut
hcv
infect
associ
certain
base
sequenc
locat
upstream
start
codon
cytokin
thio
thoma
recent
candid
gene
studi
welzel
colleagu
investig
associ
genet
hcv
treatment
respons
focu
ifnalpha
pathway
welzel
et
al
genotyp
snp
along
ifnalpha
pathway
patient
hepat
c
longterm
treatment
cirrhosi
haltc
trial
util
assay
appli
biosystem
carlsbad
ca
usa
analysi
abi
platform
appli
biosystem
focus
european
american
n
purpos
statist
power
welzel
et
al
particip
fibrosi
score
previous
respond
ifn
treatment
without
rbv
score
less
seven
treat
pegifn
rbv
week
week
undetect
week
recent
studi
welzel
colleagu
examin
snp
gene
encod
ifnalpha
ifnalpha
receptor
jaktyrosin
kinasestat
part
signal
transduct
via
pathway
ifnalphainduc
gene
antivir
properti
includ
adenosin
deaminaseeukaryot
translat
initi
factor
kinas
resist
synthetas
well
interferon
regulatori
factor
welzel
et
al
recent
studi
ke
colleagu
extend
previou
research
appli
ann
algorithm
logist
regress
featur
select
predict
ifnalpha
rbv
treatment
outcom
use
genet
factor
cohort
chc
patient
origin
previou
studi
lin
addit
rapid
patientspecif
drugresist
phenotyp
manag
antiretrovir
therapi
structur
pharmacogenom
use
predict
clinic
trial
outcom
comput
analyz
interact
put
drug
sampl
polymorph
structur
repertoir
new
drug
encount
clinic
possibl
predict
bind
effect
new
drug
initi
expens
clinic
evalu
patient
straightforward
applic
extens
recent
report
success
comput
predict
drug
resist
phenotyp
proteas
patientbypati
basi
shenderovich
et
al
interact
movement
side
chain
individu
polymorph
structur
respons
drug
bind
comput
exampl
comparison
comput
structur
chang
upon
drug
bind
observ
chang
correspond
xray
crystallograph
structur
hong
et
al
proteas
complex
sensit
specif
predict
drug
resist
phenotyp
patientbypati
basi
variou
food
drug
administr
fda
http
wwwfdagov
approv
drug
base
upon
comput
rel
energi
bind
interact
drug
patient
uniqu
drugtarget
polymorph
structur
number
appear
quit
good
comparison
achiev
laboratori
present
howev
perhap
import
respect
increas
effici
speed
drug
design
answer
gener
overnight
rather
week
typic
timefram
laboratori
drug
resist
phenotyp
anoth
way
look
interact
put
drug
drug
lead
set
drugtarget
polymorph
dock
molecul
individu
polymorph
measur
distanc
drug
residu
within
protein
analysi
five
differ
proteas
inhibitor
shown
tabl
predict
drug
efficaci
mutat
frequenc
profil
superimpos
bottom
graph
analysi
clearli
identifi
aminoacyl
side
chain
mutat
high
frequenc
close
proxim
bound
drug
proxim
stabl
distal
mutat
distal
stabl
structur
pharmacogenom
technolog
broad
applic
ration
design
highli
effect
infecti
diseas
therapi
bacteria
well
virus
drug
well
vaccin
offer
prospect
stabl
efficaci
face
drug
select
pressur
addit
natur
occur
infecti
agent
clear
signific
valu
biodefenserel
applic
ration
drug
vaccin
design
threat
assess
predict
understand
manag
advers
effect
antiretrovir
therapi
highli
activ
antiretrovir
therapi
haart
chang
landscap
hiv
diseas
way
seem
unthink
decad
ago
first
haart
regimen
work
suppress
viru
encumb
varieti
shortterm
longterm
side
effect
recent
regimen
becam
simpler
easier
take
fewer
advers
event
knowledg
short
longterm
advers
event
associ
haart
essenti
provid
patient
new
drug
accept
current
field
pass
litmu
test
toler
sinc
advers
event
often
remark
idiosyncrat
pharmacogenom
may
offer
way
predict
side
effect
sever
particular
drug
drug
class
individu
patient
advers
event
ae
play
major
role
determin
adher
highli
activ
antiretrovir
therapi
haart
adher
perhap
signific
determin
regimen
success
arminio
monfort
et
al
random
control
clinic
trial
gold
standard
evalu
efficaci
drug
may
underestim
shortterm
toxic
gener
clinic
popul
desir
subject
stay
trial
support
trial
staff
enabl
longterm
toxic
may
miss
often
younger
age
subject
clinic
trial
rel
shortterm
durat
trial
may
detect
toxic
low
preval
rate
tabl
show
advers
effect
associ
differ
class
antiretrovir
ae
antiretrovir
drug
use
divid
short
longterm
toxic
also
class
agent
use
nucleosid
analogu
nucleotid
analogu
tabl
block
synthesi
viral
dna
revers
transcriptas
enzym
phosphoryl
cellular
kinas
compound
incorpor
revers
transcriptas
nascent
chain
viral
dna
drug
lack
hydroxyl
group
addit
nucleotid
attach
synthesi
viral
dna
arrest
two
distinct
mechan
involv
hiv
resist
drug
impair
incorpor
analogu
dna
remov
analogu
prematur
termin
dna
chain
sever
mutat
group
mutat
revers
transcriptas
enzym
promot
resist
select
impair
abil
revers
transcriptas
incorpor
analogu
dna
essenti
includ
mutat
complex
mutat
mutat
tabl
mutat
involv
replac
methionin
valin
posit
revers
transcriptas
main
mutat
confer
resist
lamivudin
boucher
et
al
methionin
locat
heart
catalyt
site
revers
transcriptas
replac
valin
differ
side
chain
interfer
proper
posit
lamivudin
triphosph
within
catalyt
site
sarafiano
et
al
mutat
induc
high
level
resist
lamivudin
lamivudin
use
singl
agent
resist
strain
overtak
wildtyp
viru
week
schuurman
et
al
lamivudin
use
part
fail
regimen
haart
mutat
almost
alway
first
mutat
emerg
havlir
et
al
group
mutat
refer
complex
iversen
et
al
tabl
often
select
cours
failur
regimen
contain
stavudin
didanosin
pathway
alway
start
substitut
residu
locat
immedi
vicin
nucleotidebind
site
revers
transcriptas
follow
gradual
accumul
secondari
mutat
enhanc
resist
increas
activ
enzym
kosalaraksa
et
al
complex
rel
rare
fewer
hiv
strain
resist
nucleosid
analogu
confer
highlevel
resist
eg
lamivudin
tenofovir
analogu
iversen
et
al
interestingli
complex
markedli
frequent
mutat
seen
increas
frequenc
patient
therapi
nucleosid
nucleotid
analogu
fail
especi
regimen
includ
tenofovir
abacavir
mutat
appear
confer
resist
analogu
except
zidovudin
remov
nucleosid
analogu
termin
dna
chain
associ
group
mutat
commonli
term
thymidin
analogu
mutat
tabl
mutat
group
frequent
select
failur
drug
combin
includ
thymidin
analogu
zidovudin
stavudin
promot
resist
almost
nucleosid
nucleotid
analogu
includ
tenofovir
larder
kemp
picard
et
al
mutat
occur
gradual
order
emerg
vari
thymidin
analogu
mutat
promot
resist
foster
atp
pyrophosphatemedi
remov
nucleosid
analogu
end
termin
dna
strand
meyer
et
al
atp
pyrophosph
abund
normal
lymphocyt
particip
dnapolymer
reaction
structur
revers
transcriptas
express
thymidin
analogu
mutat
facilit
entri
site
adjac
incorpor
analogu
chamberlain
et
al
posit
atp
pyrophosph
attack
phosphodiest
bond
link
analogu
dna
result
remov
analogu
interestingli
effici
process
also
known
primer
rescu
significantli
decreas
presenc
mutat
revers
transcriptas
phenomenon
best
describ
case
mutat
larder
et
al
consequ
slow
select
thymidin
analogu
mutat
thymidin
analogu
picard
et
al
may
slightli
increas
residu
antivir
activ
nucleosid
analogu
spite
presenc
thymidin
analogu
mutat
nonnucleosid
revers
transcriptas
inhibitor
small
molecul
strong
affin
hydrophob
pocket
locat
close
catalyt
domain
revers
transcriptas
bind
inhibitor
affect
flexibl
enzym
therebi
block
abil
synthes
dna
mutat
select
failur
treatment
nonnucleosid
revers
transcriptas
inhibitor
locat
pocket
target
compound
reduc
affin
drug
esnouf
et
al
hsiou
et
al
subtl
differ
interact
variou
nonnucleosid
revers
transcriptas
inhibitor
hydrophob
pocket
howev
mutat
emerg
frequent
somewhat
drug
depend
tabl
resist
nevirapin
often
associ
mutat
mutat
also
occur
initi
resist
efavirenz
gener
character
mutat
mutat
also
seen
hiv
proteas
cleav
larg
polyprotein
precursor
specif
site
releas
structur
protein
enzym
necessari
assembl
infecti
viral
particl
absenc
function
proteas
viral
particl
produc
immatur
infecti
proteas
hiv
symmetr
assembl
homodim
central
symmetr
substratebind
caviti
detail
knowledg
structur
domain
structur
natur
protein
substrat
enzym
led
design
specif
inhibitor
whose
chemic
structur
mimic
viral
peptid
normal
recogn
cleav
proteas
robert
et
al
compound
display
strong
affin
activ
site
hiv
proteas
inhibit
catalyt
activ
enzym
highli
select
manner
resist
proteas
inhibitor
consequ
amino
acid
substitut
emerg
either
insid
substratebind
domain
enzym
distant
site
molla
et
al
tabl
directli
indirectli
amino
acid
chang
modifi
number
natur
point
contact
inhibitor
proteas
therebi
reduc
affin
enzym
hong
et
al
prabujeyabalan
et
al
exampl
common
resist
mutat
reduc
size
amino
acid
residu
proteas
import
bind
inhibitor
bind
natur
viral
protein
substrat
prabujeyabalan
et
al
proteas
inhibitor
design
bind
proteas
maxim
affin
tend
occupi
space
insid
activ
site
caviti
natur
substrat
unlik
inhibitor
natur
substrat
proteas
variabl
gener
less
tight
interact
catalyt
site
phenomenon
promot
order
sequenti
cleavag
polyprotein
requir
proper
assembl
viral
particl
resist
mutat
proteas
result
overal
enlarg
catalyt
site
enzym
would
thu
predict
greater
effect
bind
inhibitor
natur
templat
mutat
select
certain
proteas
inhibitor
tabl
reflect
particular
chemic
structur
inhibitor
influenc
interact
substratebind
domain
enzym
howev
consider
overlap
combin
mutat
hiv
strain
develop
resist
proteas
inhibitor
overlap
explain
wide
crossresist
gener
observ
within
drug
class
schapiro
et
al
remark
resist
proteas
inhibitor
also
promot
mutat
natur
viral
substrat
proteas
mammano
et
al
characterist
substitut
amino
acid
near
cleavag
site
gag
polyprotein
identifi
increas
level
resist
replic
capac
viru
facilit
cleavag
condit
amount
activ
enzym
suboptim
improv
abil
proteas
contain
resist
mutat
interact
substrat
enter
target
cell
intric
sequenc
interact
hiv
envelop
glycoprotein
gp
complex
specif
cellsurfac
receptor
kilbi
eron
earli
step
process
allow
fusogen
compon
complex
interact
cell
membran
therebi
tether
viru
target
membran
viru
target
cell
brought
close
proxim
foster
fusion
rearrang
step
distal
hydrophob
region
fold
onto
proxim
hydrophob
region
effect
shorten
molecul
enfuvirtid
peptid
deriv
destabil
process
bind
block
infect
viral
resist
enfuvirtid
usual
result
mutat
locat
stretch
ten
amino
acid
within
rimski
et
al
interestingli
chang
amino
acid
outsid
hr
even
chang
appear
associ
signific
differ
suscept
viru
enfuvirtid
mutat
polymorph
probabl
explain
remark
wide
rang
natur
suscept
enfuvirtid
among
strain
derdeyn
et
al
reev
et
al
could
particip
evolut
acquir
resist
enfuvirtid
crossresist
defin
resist
drug
viru
never
expos
result
mutat
select
use
anoth
drug
crossresist
alway
restrict
drug
within
given
class
antiretrovir
agent
three
class
antiretrovir
drug
affect
earli
evolut
resist
nucleosid
analogu
proteas
inhibitor
virus
may
low
level
crossresist
altern
agent
within
two
class
drug
richman
nevertheless
strain
may
need
add
one
addit
mutat
preexist
scaffold
highlevel
crossresist
develop
therefor
patient
infect
strain
low
level
crossresist
switch
appar
activ
altern
drug
accompani
rapid
select
highli
resist
variant
expens
minim
evolutionari
chang
dulioust
et
al
resist
allornoth
phenomenon
gener
increas
time
richman
barbour
et
al
ross
et
al
singl
mutat
rare
produc
complet
resist
antiretrovir
drug
although
mutat
revers
transcriptas
result
complet
resist
lamivudin
except
rule
singl
mutat
hydrophob
pocket
revers
transcriptas
also
provid
strong
resist
nonnucleosid
revers
transcriptas
inhibitor
viral
strain
patient
regimen
use
drug
fail
often
incur
addit
mutat
suggest
level
resist
provid
singl
mutat
optim
hanna
et
al
resist
revers
transcriptas
inhibitor
accumul
thymidin
analogu
mutat
complex
mutat
resist
proteas
inhibitor
alway
gradual
process
lead
progress
increas
level
resist
mammano
et
al
nonetheless
even
sever
mutat
accumul
hiv
proteas
revers
transcriptas
suffici
produc
patent
treatment
failur
resist
may
reach
maxim
level
addit
mutat
associ
increas
resist
occur
even
absenc
chang
treatment
barbour
et
al
inde
develop
complet
resist
may
repres
except
resist
mutat
impair
viral
replic
capac
solut
adopt
domin
viral
popul
may
entail
make
concess
term
resist
effort
made
evalu
antivir
activ
retain
individu
drug
face
resist
mutat
knowledg
may
help
treatment
patient
infect
virus
express
resist
multipl
class
drug
sinc
keep
hiv
pharmacolog
pressur
may
reduc
pathogen
potenti
mani
resist
mutat
impair
viral
replic
mutat
modifi
key
viral
protein
deleteri
effect
variabl
extent
protein
function
although
deficit
partial
correct
compensatori
mutat
nijhui
et
al
virus
forc
develop
higher
level
resist
intens
continu
pressur
antiretrovir
drug
often
substanti
impair
replic
capac
barbour
et
al
degre
replic
impair
confer
resist
mutat
highli
variabl
crippl
mutat
appear
associ
resist
proteas
inhibitor
zennou
et
al
signific
replic
defect
relat
mutat
revers
transcriptas
confer
resist
nucleosid
analogu
nonnucleosid
revers
transcriptas
inhibitor
back
et
al
bleiber
et
al
well
envelop
mutat
associ
resist
enfuvirtid
clinic
effect
resistanceassoci
loss
viral
replic
capac
subject
intens
investig
sever
observ
suggest
resist
virus
lost
virul
antiretrovir
treatment
interrupt
patient
infect
hiv
resist
multipl
drug
resist
strain
less
rapidli
replac
wildtyp
viru
chang
accompani
drop
tcell
count
suggest
wildtyp
viru
greater
replic
pathogen
potenti
deek
et
al
signific
proport
patient
haart
fail
tcell
count
remain
significantli
pretreat
level
despit
poor
control
replic
kaufmann
et
al
whether
appar
immunolog
benefit
haart
spite
patent
virolog
failur
direct
consequ
reduc
viral
pathogen
sign
persist
residu
activ
drug
regimen
remain
elucid
consequ
therapeut
strategi
take
advantag
resistanceassoci
loss
hiv
replic
capac
yet
identifi
howev
recent
data
catch
usbas
studi
suggest
transmit
drugresist
hiv
remain
domin
popul
peripher
blood
extend
period
time
furthermor
studi
analyz
baselin
nucleotid
sequenc
among
subject
primari
hiv
infect
show
variat
antiretrovir
therapi
littl
et
al
patient
infect
approxim
day
least
one
major
drug
resist
mutat
longitudin
sampl
collect
median
day
infect
analyz
persist
transmit
drugresist
variant
seven
patient
evid
nnrti
resist
two
patient
resist
nrti
pi
one
patient
tripleclass
resist
averag
time
revers
variant
mix
nk
popul
seven
patient
nnrti
resist
day
follow
estim
date
infect
four
patient
mutat
confer
resist
proteas
inhibitor
revers
wild
type
detect
day
infect
complet
revers
genotyp
resist
observ
one
patient
day
infect
dr
kuritzk
conclud
data
present
croi
team
investig
gilead
scienc
borrotoesoda
et
al
studi
compar
oncedaili
emtricitabin
emtriva
oncedaili
stavudin
zerit
combin
didanosin
videx
efavirenz
sustiva
patient
north
america
latin
america
europ
overal
evalu
patient
enter
studi
hiv
mutat
posit
associ
resist
nnrti
differ
preval
type
mutat
group
subject
wildtyp
viru
baselin
incid
virolog
failur
stavudin
group
emtricitabin
group
among
patient
drugresist
viru
baselin
virolog
failur
occur
stavudin
group
emtricitabin
group
perhap
wide
cite
case
point
regard
danger
glaxosmithklin
trial
gallant
et
al
studi
patient
random
receiv
either
tenofovir
efavirenz
combin
fixeddos
combin
tablet
contain
mg
abacavir
mg
lamivudin
taken
day
patient
antiretrovir
therapi
prior
start
studi
averag
baselin
viral
load
copiesml
baselin
cell
count
glaringli
high
number
treatment
failur
document
triplenrti
group
studi
investig
conduct
unplan
analysi
involv
first
patient
complet
week
followup
approxim
patient
triplenrti
group
met
definit
virolog
failur
compar
patient
efavirenzbas
arm
tenofovir
abacavir
lamivudin
select
mutat
among
patient
viral
load
high
enough
test
drug
resist
mutat
tenofovir
abacavir
lamivudin
exert
concert
pressur
locu
emerg
singl
mutat
abl
abrog
efficaci
regimen
singl
stroke
nrti
exert
block
effect
plug
nonextend
nucleosid
analogu
monophosph
end
grow
provir
dna
chain
effect
termin
chain
extens
ultim
inhibit
replic
viru
howev
process
revers
revers
transcriptas
reaction
remov
chaintermin
residu
reinstat
extend
primer
revers
reaction
dna
polymer
term
pyrophosphorolysi
enabl
revers
transcript
dna
synthesi
resum
pyrophosphorolysi
enhanc
key
mutat
often
refer
thymidin
analogu
mutat
tam
pyrophosphorolysi
believ
primari
mechan
resist
zidovudin
stavudin
process
drug
specif
way
discriminatori
mutat
tend
consequ
pyrophosphorolysisenhanc
mutat
confer
reduc
suscept
nrti
essenc
nrti
resist
sum
two
mechan
abil
alter
drug
bind
incorpor
mechan
describ
begin
section
plu
abil
alter
excis
drug
nascent
dna
chain
mutat
imped
drug
bind
primer
excis
effect
variant
harbor
tam
still
consid
rare
occurr
surpris
effect
mani
tam
finger
domain
polymeras
make
deoxynucleotid
triphosph
bind
site
turn
tam
interfer
proper
function
enzym
imped
primer
excis
believ
sensit
hiv
nrti
affect
tam
notabl
zidovudin
also
note
tam
revers
effect
drug
bind
incorpor
data
suggest
concurr
zidovudin
use
prevent
emerg
mutat
though
mechan
respons
yet
elucid
interest
data
six
recent
clinic
trial
evalu
revers
transcriptas
inhibitor
regimen
contain
tenofovir
either
without
zidovudin
among
patient
initi
therapi
first
time
tenofovirinclus
regimen
involv
zidovudin
much
like
fail
associ
develop
mutat
convers
tenofovir
zidovudineinclus
regimen
much
like
fail
associ
develop
tam
move
resist
issu
heavili
pretreat
hivposit
patient
dr
kuritzk
review
data
stem
actg
clinic
trial
design
determin
whether
addit
second
proteas
inhibitor
regimen
contain
amprenavir
ageneras
improv
respons
salvag
therapi
mellor
et
al
studi
enrol
heavili
pretreat
hivposit
patient
one
proteas
inhibitor
past
two
prior
proteas
inhibitor
past
three
proteas
inhibitor
past
approxim
patient
also
nnrti
past
patient
receiv
efavirenz
adefovir
dipivoxil
abacavir
amprenavir
addit
subject
random
receiv
either
placebo
nelfinavir
viracept
saquinavir
fortovas
indinavir
crixivan
statist
signific
differ
three
activ
drug
arm
howev
signific
differ
combin
activ
arm
placebo
arm
demonstr
dual
proteas
inhibitor
regimen
superior
singl
proteas
inhibitor
regimen
heavili
pretreat
patient
surprisingli
actg
investig
report
nnrtinaiv
patient
significantli
better
respons
nnrtiexperienc
patient
nnrtiexperienc
patient
compar
nnrtinaiv
patient
fail
achiev
undetect
viral
load
week
followup
interest
though
analysi
nnrtiexperienc
patient
week
howev
differ
respons
rate
two
group
becam
insignific
eventu
converg
review
recent
work
area
thymidin
analogu
mutat
review
studi
result
explain
certain
tam
tend
occur
togeth
other
rare
found
togeth
viru
exampl
pathway
common
tam
pattern
associ
highlevel
resist
zidovudin
crossresist
nrti
includ
tenofovir
abacavir
contrast
pathway
isol
less
common
tam
pattern
associ
lower
fold
resist
cluster
also
show
mutat
rare
appear
revers
transcriptas
virus
also
harbor
mutat
mutat
kuritzk
diverg
tam
pathway
hu
et
al
nutshel
studi
found
isol
carri
mutat
replic
effici
isol
harbor
mutat
incorpor
mutat
isol
harbor
mutat
viral
fit
substanti
reduc
convers
incorpor
mutat
isol
harbor
mutat
substanti
growth
advantag
presenc
zidovudin
hu
et
al
thu
conclud
pathway
common
confer
higherlevel
resist
zidovudin
nrti
wherea
virus
carri
lower
replic
capac
poorli
fit
respect
mutat
confer
signific
advantag
hiv
presenc
zidovudin
mutat
play
much
larger
role
develop
zidovudin
resist
usual
consid
kuritzk
perhap
bestknown
revers
transcriptas
mutat
known
caus
highlevel
resist
lamivudin
emtricitabin
howev
studi
suggest
highlevel
resist
lamivudin
necessarili
mean
drug
render
worthless
exampl
phenomenon
found
clinic
trial
partial
treatment
interrupt
conduct
dr
steven
deek
colleagu
deek
et
al
studi
focus
cohort
hivposit
individu
histori
excel
treatment
adher
drugresist
viremia
greater
copiesml
experienc
document
treatmentmedi
benefit
eg
viral
load
cell
count
pretreat
level
patient
either
stop
pi
nrti
determin
select
effect
two
drug
class
term
maintain
lessfit
viru
one
studi
discontinu
lamivudin
four
highli
treatmentexperienc
patient
viabl
altern
treatment
option
evid
mutat
regimen
consist
least
three
antiretrovir
campbel
et
al
six
week
stop
lamivudin
hiv
rna
level
increas
averag
copiesml
baselin
even
though
mutat
remain
detect
viru
patient
basic
show
us
even
presenc
mutat
lamivudin
still
contribut
hiv
rna
suppress
revers
wild
type
occur
four
patient
week
accompani
addit
averag
increas
viral
load
copiesml
upon
resum
lamivudin
therapi
mutat
reappear
within
week
four
patient
colat
trial
openlabel
trial
involv
patient
experienc
virolog
failur
lamivudinecontain
regimen
dragst
et
al
switch
anoth
regimen
approxim
half
patient
random
continu
lamivudin
therapi
remain
patient
random
discontinu
lamivudin
treatment
fortyeight
week
later
signific
differ
two
group
pharmacogenom
examin
influenc
genet
variabl
drug
efficaci
toxic
correl
gene
express
singlenucleotid
polymorph
patient
outcom
predict
studi
mallal
et
al
show
presenc
allel
highli
predict
hsr
abc
posit
neg
predict
valu
respect
use
genet
test
led
reduct
abcrel
hsr
ari
trial
squir
et
al
compar
rate
seen
trial
use
hla
screen
first
exampl
clinic
use
genet
screen
hiv
diseas
manag
get
widespread
approv
potenti
mutat
posit
signal
longer
halflif
increas
level
efavirenz
haa
et
al
haplotyp
within
associ
longer
halflif
nevirapin
chantarangsu
genet
variant
associ
gilbert
diseas
ugt
identifi
part
haplotyp
four
variant
span
three
gene
gene
locu
lankisch
et
al
initi
assess
perform
small
cohort
patient
tdfassoci
renal
dysfunct
identifi
singl
substitut
posit
gene
potenti
associ
side
effect
izzedin
et
al
exampl
nucleotid
variat
posit
human
pglycoprotein
gene
number
patient
genotyp
group
cc
ct
tt
still
experienc
virolog
suppress
month
respect
p
brumm
et
al
greater
patient
regimen
nrti
plu
pi
small
effect
though
signific
slower
time
immunolog
virolog
failur
cc
genotyp
pharmacogenom
provid
miracul
opportun
bring
chang
clinic
practic
medicin
health
due
upcom
research
field
also
help
minim
toxic
advers
effect
correl
newli
found
resist
mutat
histor
antiretrovir
use
could
interest
clinician
plan
subsequ
antiretrovir
regimen
patient
undergon
rang
treatment
molecular
diagnost
test
made
less
expens
make
abl
give
imper
therapi
viral
diseas
aidshiv
hepat
current
give
enorm
econom
burden
howev
happen
need
major
technolog
improv
abil
sequenc
screen
genom
dna
assess
individu
genom
context
popul
data
extens
populationbas
studi
requir
evalu
phenotyp
signific
acut
long
term
genom
variat
level
individu
variant
combin
variant
clinic
trial
must
carri
goal
identifi
outcom
variou
combin
genom
expressionbas
metabolom
proteom
data
arriv
complet
clinicogenom
profil
predict
diseas
risk
drug
respons
effort
jointli
open
new
ray
hope
miracul
chang
histori
medicin
peopl
suffer
viral
diseas
